Spago Nanomedical AB (SE:SPAGO)

:SPAGO

SPAGO

Spago Nanomedical AB

RESEARCH TOOLSreports

Want to see SE:SPAGO full AI Analyst Report?

Spago Nanomedical AB (SPAGO) Price & Analysis

0 Followers

SPAGO Stock Chart & Stats

kr0.10

kr0.00(0.00%)

At close: Mar 06 4:00 PM EST

kr0.10

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr0.08 - kr0.33

Previous CloseN/A

Volume33.85K

Average Volume (3M)1.01M

Market Cap

kr91.30M

Enterprise Valuekr22.30M

Total Cash (Recent Filing)kr25.92M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.04

Shares Outstanding661,572,800

10 Day Avg. Volume1,158,815

30 Day Avg. Volume1,005,829

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.42

Price to Sales (P/S)99.92

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Zero Debt / Low LeverageZero reported debt materially reduces refinancing and interest-rate risk for a pre-revenue biotech. For a company burning cash on clinical programs, low leverage preserves optionality for equity or partnership funding, lowering the odds of distress and supporting multi‑stage R&D timelines.

Narrowing Net LossesA sustained reduction in net losses across years signals improving expense control or more efficient program spending. Over 2–6 months this trend supports greater runway visibility and indicates management can compress burn per development milestone, improving chances to reach value‑creating inflection points.

Focused Nanomedicine R&D PipelineA clear strategic focus on nanoparticle diagnostics and targeted radiotherapy builds domain expertise and potential differentiation. If clinical validation continues, the specialized platform can create barriers to entry, drive licensing or partnership opportunities, and align with long‑term oncology diagnostic and theranostic trends.

Bears Say

Persistent Negative Operating Cash FlowConsistently negative operating cash flow indicates the business consumes cash to fund R&D and operations, necessitating external financing or partnerships. Over the medium term this raises dilution risk, can constrain program sequencing, and forces management to prioritize funding over optional long‑term investments.

Very Small, Volatile RevenueA low and highly variable revenue base undermines internal funding capacity and shows the business is not yet commercially resilient. Structural revenue volatility makes multi‑stage clinical funding and commercial planning harder, increasing reliance on external capital or partnerships to sustain programs.

Erosion Of Equity And Negative Returns On EquityDeclining equity and deeply negative ROE reflect sustained losses eroding shareholder value. This weakens balance‑sheet resilience, can raise the cost of future equity raises, and signals that current operations are destroying rather than creating capital unless clinical or commercial milestones reverse the trend.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.08 and its highest was kr0.33 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr91.30M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on May 07, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 661,572,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.